Evidence map›Paper›PMID 41761123›Full record

ArticleBMC cancer2026

Spatial atlas of gastric cancer reveals macrophage-driven stromal activation via ICAM1⁺ smooth muscle cells.

Kang Cheng, Jingquan Xu, Jianlei Yang, Zili Zhang

Abstract read
In one paragraph

Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kang ChengDepartment of Gastrointestinal Surgical Oncology, Central Hospital, Tianjin University/Tianjin Third Central Hospital, Tianjin, 300170, People's Republic of China.
Jingquan XuDepartment of Gastrointestinal Surgical Oncology, Central Hospital, Tianjin University/Tianjin Third Central Hospital, Tianjin, 300170, People's Republic of China.
Jianlei YangDepartment of Gastrointestinal Surgical Oncology, Central Hospital, Tianjin University/Tianjin Third Central Hospital, Tianjin, 300170, People's Republic of China.
Zili ZhangDepartment of Gastrointestinal Surgical Oncology, Central Hospital, Tianjin University/Tianjin Third Central Hospital, Tianjin, 300170, People's Republic of China. tjszxchk@163.com.

Funding

Key Project of the Tianjin Natural Science Foundation 21JCZDJC00240Tianjin "131" Innovative Talent Team Project 201939Tianjin Key Medical Discipline (Specialty) Construction Project TJYXZDXK-035A
6 · The paper itself

Abstract

backgroundStromal remodeling constitutes a hallmark of gastric cancer (GC) progression, yet the intercellular signaling networks orchestrating this process remain incompletely understood.

methodsSingle-cell RNA sequencing (scRNA-seq) data from 172,763 cells (GSE167297: n = 30,365; OMIX001073: n = 142,398) were integrated with spatial transcriptomic profiles from 10 GC samples (GSE251950). The analyses encompassed single-cell integration, spatial deconvolution, spatial architecture reconstruction, identification of tertiary lymphoid structures (TLSs), and inference of intercellular communication networks. Clinical relevance was evaluated through survival analyses across multiple independent public cohorts. Key computational findings were validated using multiplex immunofluorescence staining, quantitative real-time PCR, and transwell co-culture migration assays.

resultsA single-cell–resolved spatial atlas of the GC tumor microenvironment (TME) was constructed. Spatial–cellular integration revealed aberrant immune cell redistribution, with enrichment of CD4⁺CXCL13⁺TOX2⁺ and CD8_Trm-ZNF683⁺ T cells in paratumor regions, indicating potential roles in immune surveillance and tumor restraint. Spatial architecture delineated six distinct microenvironmental niches: C0 (immune-active, TLS-enriched), C1 (dendritic cell-dominant, immunoregulatory), C2 (immune–stromal interface), C3/C4 (epithelial-rich tumor cores), and C5 (stromal-supportive). TLSs were predominantly localized within the immune-active C0 niche, representing mature immune hubs. Within the stromal C5 niche, a coordinated stromal activation mechanism was identified, mediated by a macrophage–smooth muscle cell (SMC)–fibroblast axis driven by synergistic macrophage-derived ITGB2–ICAM1 and OSM–OSMR signaling. Immunofluorescence co-localization and qPCR assays confirmed elevated expression of OSM, OSMR, ITGB2, and ICAM1 in tumor tissues. Functionally, Functionally, transwell co-culture assays demonstrated that macrophage-derived OSM and ITGB2 were associated with enhanced SMCs proliferation and migratory capacity, while silencing either molecule significantly attenuated this effect. This dual signaling axis promoted ICAM1⁺ SMC proliferation and activation through PI3K/Akt pathway engagement and extracellular matrix (ECM) remodeling, resulting in extensive stromal reorganization and a pro-tumorigenic microenvironment. Across multiple cohorts, concurrent activation of ITGB2 and OSM pathways was associated with significantly poorer overall survival compared with activation of either pathway alone, underscoring the prognostic and therapeutic relevance of this interaction.

conclusionsThis study reconstructs the GC spatial architecture at single-cell resolution, and reveals a previously unrecognized macrophage-driven stromal activation program mediated by convergent ITGB2–ICAM1 and OSM–OSMR signaling. ICAM1⁺ SMCs emerge as key effectors and potential targets for stromal-directed therapy.

Indexed as

Intercellular Adhesion Molecule-1MacrophagesStomach NeoplasmsStromal CellsCell Line, TumorCoculture TechniquesGene Expression Regulation, NeoplasticHumansSingle-Cell AnalysisSingle-Cell Gene Expression AnalysisSpatial TranscriptomicsTumor MicroenvironmentICAM1 protein, humanIntercellular Adhesion Molecule-1Gastric cancer (GC)ITGB2-ICAM1Single-cell atlasSpatial transcriptomicsTissue architectureTumor microenvironment (TME)

Identifiers

PMID41761123
PMCPMC13067741

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.